EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
From Single-Cell to Spatial Intelligence: The Next Era of Precision Medicine
Founder & Strategic Advisor, Genomics Consult
Dr Elsa Molina is a PhDtrained biologist and strategic scientific leader specializing in singlecell genomics spatial omics and nextgeneration sequencing technologies With over eight years of experience at the Salk Institute and University of California San Diego her background spans Europe Australia and North America Dr Molina is Founder Strategic Advisor at Genomics Consult advising on translati...
Articles
Green Synthesis of Metallic Nanoparticles
Nanotechnology has transformed the pharmaceutical landscape offering revolutionary solutions in drug delivery diagnostics and therapeutics However traditional methods of synthesizing nanoparticles often rely on hazardous chemicals consume high energy and generate toxic byproducts As the industry leans toward sustainable practices green synthesis emerges as a powerful natureinspired alternative Thi...
Research Insights
Feasibility of the Inhibitor Development for Cancer: A Systematic Approach for Drug Design
The traditional Chinese medicine TCM bupleurumgingerlicorice formula presents significant anticancer effects but its active ingredients and inhibitory mechanism remain unclear In this work the core effective ingredient quercetin and its signal transducer and activator of transcription
Case Studies
Glucose Oxidase Stabilised in OxyzymeT - a commercial wound dressing
Partner nsense Ltd is a specialty wound care company that has developed a range of novel active hydrogelbased dressings OxyzymeT and IodozymeT which are capable of active delivery of oxygen iodine and nitric oxide to a wound site
Techno Trends
World's Fist-of-its-Kind Drug Delivery Device Launched for Precise Dosing of Cannabis
Syqe Medical launched the worlds first pharmaceuticalgrade metereddose cannabis inhaler in Israel The eight years of research and development including rigorous testing through multiple clinical trials paved a novel regulatory path
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Harnessing Artificial Intelligence
Anita-Ioana Visan, a Scientific Researcher 2nd degree, at the Laser-Surface-Plasma Interactions (LSPI) Laboratory, Lasers Department, National Institute for Lasers, Plasma and Radiation Physics (INFLPR) in Magurele, is an expert in nanopowders synthesis and characterisation, as well as thin coatings of calcium phosphates, biopolymers, flavonoids, antibiotics, and antimicrobial peptides synthesized by Pulsed Laser Deposition, Matrix Assisted Pulsed Laser Evaporation, and Combinatorial-MAPLE. Moreover, she has a profound knowledge of thin films characterisation methods, including UV-Vis, FTIR, XRD, SEM, AFM, fluorescence microscopy, electrochemical, magnetic induction, biodegradation, and antimicrobial tests. With her current research focusing on the cutting-edge fields of artificial neural networks, drug repurposing, and pharmaceutical AI, she is paving the way for innovative solutions that have the potential to revolutionise the field of medicine. If you would like to contact her, please use the following email address: anita.visan@inflpr.ro. Furthermore, you can find her professional profile at https://orcid.org/0000-0003-0539-4160.
Irina Negut is a Scientific Researcher 2nd degree, at the National Institute for Lasers, Plasma and Radiation Physics (INFLPR) in Magurele, Romania. She has important experience in fabricating and investigating the characteristics and (bio) functionality of nano-sized/-structured materials (including composite and hybrid particles, thin films and laser-processed coatings). Her research activity includes coating synthesis by laser-assisted techniques. She is also highly experienced in evaluating the compositional and microstructural aspects of nanomaterials and coatings, but also in assessing their optical, thermal, electrical, and electrochemical properties. If you would like to contact her, please use the following email address: negut.irina@inflpr.ro. Her professional profile can be found at https://orcid.org/0000-0003-4038-7548.
Boosting NICU Safety
Norhan Attia, clinical pharmacist with five years' experience at Assiut University Hospital, Egypt, specialising in Neonatal Intensive Care. Expert in medication reviews, IV admixtures, and optimising pharmacotherapy outcomes. Currently a dedicated teaching assistant, focusing on pharmaceutical education and enhancing medication safety in NICU settings.
Artificial Intelligence in Oncology
Nancy Kapila is a seasoned pharmaceutical consultant with over 5 years of varied experience and a Master’s in Pharmaceutics from Panjab University. She excels in drug mechanisms and interactions. Her career highlights include collaborating with numerous pharmaceutical companies and offering strategic insights and guidance. Nancy stands out for her dedication to keeping abreast of pharmaceutical advancements, regulatory changes, and emerging trends. She believes in continuous learning to navigate the industry’s complexities and provide innovative client solutions. Fascinated by the role of data analytics in decision-making, Nancy delves into data to uncover patterns and opportunities, offering evidence-based recommendations for process optimization, product development, and operational efficiency. Her career is driven by a relentless pursuit of knowledge, passion for data insights, and commitment to leading pharmaceutical companies towards success in a dynamic industry.
Incipient Biopharmaceutical Claims of Milk Derived Exosomes
Rakesh K. Tekade is a formulation researcher with of teaching and research experience. He has an explicit experience of over 10 years in teaching various modules for Ph.D, Masters & Bachelors students (@ Universities based in USA, UK, Malaysia, & India). He currently serving as Associate Professor at NIPER-Ahmedabad (An Institute of National Importance Government of India). Prior to this, Dr. Tekade was faculty at International Medical University, Kuala Lumpur, Malaysia. He took his postdoctoral trainings from UT Southwestern Medical Centre, Dallas, Texas, USA and University of Hawaii, Hilo, Hawaii, USA. He is a recipient of Commonwealth Fellowship at University of Central Lancashire, Preston, UK. Recently, Dr Tekade has been listed as Top 2% researcher in the field of Pharmacy and Pharmacology, by Stanford University, USA.
Nupur Vasdev is currently pursuing her PhD in the department of pharmaceutics from NIPER-Ahmedabad. She has completed M.S (Pharm.) in pharmaceutics from NIPER-Raebareli. She is currently working on targeted nano particulate drug delivery for obesity and cancer. Her research focus also includes surface modified exosome drug delivery for cancer and obesity.
Manisha Choudhary is currently pursuing her M.S. (Pharm) in Pharmaceutics at NIPER-Ahmedabad, India. She is currently working on aptamer decorated nanomaterials for improving the targeting. Her work majorly focuses on the improvement of the stability, targeting and robustness of aptamer conjugated nanomaterials for cancer treatment. Her work also focusses on the extraction of natural derived exosomes.
Suryanarayana Polaka is currently pursuing his PhD at NIPER-Ahmedabad, India. He is working in targeted drug delivery systems for the treatment of rheumatoid arthritis and wound healing. He also works on exosome mediated drug delivery. He co-authored 10 peer-reviewed publications in international journals, contributed > 7 international reference book chapters.
Professor Kiran Kalia is a currently serving as Director and Professor at NIPER-Ahmedabad. Her work basically focused on the Proteomic markers for diabetic nephropathy, diabetic retinopathy and metal toxicity studies. Recently she started exploring the exosomes mediated drug delivery for delivering the genes for treating various ailments like cancer, wounds and diabetic nephropathy.
Demystifying Lead-time bias and Length-time bias in Clinical Trials
Jefry Winner G has completed his MBBS from Vinayaka Missions Medical College. He is currently pursuing a Doctorate of Medicine in Pharmacology at JIPMER Puducherry. He is interested in clinical research and is currently involved in an academic clinical trial involving Epilepsy. He has four years of clinical experience in healthcare and Academia. His area of interest includes Clinical trials, Pharmacotherapeutics, Drug safety, and clinical pharmacology. He also has over 15 publications in peer-reviewed journals.
press releasesRead more...
Enhertu approved in the EU as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer
AstraZeneca and Daiichi Sankyos Enhertu trastuzumab deruxtecan has been approved in the European Union EU as a monotherapy for the adjuvant treatment of adult patients with resected HERpositive breast cancer who have residual invasive disease after neoadjuvant taxanebased and HERtargeted treatment
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
Teva Pharmaceuticals International GmbH a subsidiary of Teva Pharmaceutical Industries Ltd today announced that it has completed the acquisition of assets from BioXcel Therapeutics Inc including worldwide rights to BXCL BXCL is an investigational dexmedetomidine
Ferring Pharmaceuticals and Gameto sign agreement for proposed acquisition
Ferring Pharmaceuticals and Gameto today announced that they have signed an agreement for a global transaction under which Ferring would acquire Gameto Completion remains subject to customary and other closing conditions Until closing the companies will continue to operate independently
Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma
Innovent Biologics Inc a worldclass biopharmaceutical company that develops manufactures and commercializes high quality medicines for the treatment of cancer metabolic autoimmune and other major diseases today announced that a New Indication Application for sintilimab in combination with Nolgileuce...
Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent
The Menarini Group Menarini a leading international pharmaceutical and diagnostics company and Stemline Therapeutics Inc Stemline a whollyowned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients along with Georgiamune Inc a clinicalstage biot...
Aptar Pharma Acquires Pulmotree, Expanding Growth Opportunities in Next-Generation Pulmonary Drug
Aptar Pharma a global leader in drug delivery dosing protection technologies and services today announced the strategic acquisition of PULMOTREE a Munich Germanybased life science company specializing in pulmonary drug delivery systems for targeted delivery to the lungs The acquisition is expected t...
EventsRead more...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026PM& AC 2026
Novotel Hyderabad Convention C...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
LATEST NEWSRead more...
Astellas Enters into Agreement with Audax for Immuno-Oncology Candidate DAX-044
Astellas Pharma and Audax Biosciences have entered into an exclusive option and licence agreement for DAX an investigational antibodycytokine fusion being developed for cancer immunotherapy DAX is designed to deliver interleukin IL an immuneactivating protein more selectively to the tumour microenvi...
Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia
Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement
Pfizer’s TALZENNA Plus XTANDI Approved for Earlier Treatment of Metastatic Prostate Cancer
Pfizer has received approval from the US Food and Drug Administration FDA to expand the use of TALZENNA talazoparib in combination with XTANDI enzalutamide for men with metastatic prostate cancer that is sensitive to hormone treatment and has specific homologous recombination repair HRR gene mutatio...
Okomera Signs Agreement with Servier for Cancer Research Technology
Okomera has signed a commercial agreement with Servier to support the development of new cancer treatments using its tumour miniaturisation technology More than of oncology drug candidates fail to reach the market making it important to identify promising treatments at an early stage Okomeras platf...
AstraZeneca and Oracle Launch Global AI Collaboration to Optimise Clinical Trials
AstraZeneca and Oracle Health and Life Sciences have launched a global collaboration to use artificial intelligence AI realworld data and cloud technology to improve clinical trial efficiency and patient outcomes The collaboration will combine AstraZenecas expertise in drug development clinical rese...
UCB Receives Approval for ZILBRYSQ Autoinjector for Adults with Generalised Myasthenia Gravis
UCB has received approval from the US Food and Drug Administration FDA for a new autoinjector option for ZILBRYSQ zilucoplan a treatment for adults with generalised myasthenia gravis gMG who test positive for antiacetylcholine receptor AChR antibodies